Odyssey Therapeutics Drug Candidate Shows Positive Phase 2a Results for Ulcerative Colitis

Odyssey Therapeutics' experimental drug, OD-001, achieved its primary endpoint in a Phase 2a clinical trial for moderate-to-severe ulcerative colitis. The oral inhibitor demonstrated a mean reduction in modified Mayo score and showed promising rates of clinical and symptomatic remission, with good tolerability. These positive results strengthen the drug's clinical proof of concept and could pave the way for further development, offering a potential new treatment option for patients.